NCT04739072Recruiting
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 2 Feb 2021
- Start date
- 22 Nov 2019
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Colorectal cancer
- NCT number
- NCT04739072
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 22 Nov 2019 to the primary completion date, 31 Dec 2028
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Other illness
- Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
Who the study is looking for
- Age ≥ 18 years.
- Histological/cytological confirmation of colorectal adenocarcinoma.
- Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
- Ability to understand and the willingness to sign a written informed consent document.
- Willing to pursue standard of care surveillance post completion of curative therapies.
- Willing to provide blood samples for correlative research.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Luke's Cancer Institute Coordinator of this site? Confirm its status | Boise | United States | Terminated |
| Cooper Hospital UNIV MED CTR. Coordinator of this site? Confirm its status | Camden | United States | Terminated |
| UT Southwestern/Simmons Cancer Center-Dallas Coordinator of this site? Confirm its status | Dallas | United States | Terminated |
| Banner MD Anderson Cancer Center Coordinator of this site? Confirm its status | Gilbert | United States | Terminated |
| The Queen's Medical Center Coordinator of this site? Confirm its status | Honolulu | United States | Terminated |
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Houston Methodist Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Terminated |
| Baptist MD Anderson Cancer Center Coordinator of this site? Confirm its status | Jacksonville | United States | Terminated |
| UT Health San Antonio - MD Anderson Cancer Center Coordinator of this site? Confirm its status | San Antonio | United States | Terminated |
| Baylor Scott & White Research Institute Coordinator of this site? Confirm its status | Temple | United States | Terminated |
This page is information, not medical advice. Discuss any trial with your doctor.